MedTrace Logo

Effects of Chantix on Relapse Prevention for Smoking Cessation

NCT00948649 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2010-08-17

No results posted yet for this study

Summary

The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.

Conditions

  • Nicotine Dependence

Interventions

DRUG

Placebo

Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.

DRUG

Varenicline

Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily

Sponsors & Collaborators

Principal Investigators

  • Caryn Lerman, Ph.D. · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-08-31
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00948649 on ClinicalTrials.gov